ロード中...
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
SIMPLE SUMMARY: Surrogate radiology-based endpoints such as progression-free survival (PFS) and objective response rate (ORR) are commonly used in oncology. However, their surrogacy with overall survival (OS) has not been evaluated in immunotherapy trials for hepatocellular carcinoma (HCC). We found...
保存先:
| 出版年: | Cancers (Basel) |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7796103/ https://ncbi.nlm.nih.gov/pubmed/33396833 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13010090 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|